New Opportunity: IsoRay Inc. (NYSE American: ISR)
Today’s newest idea is a company that is pursuing a potentially disruptive cancer treatment using Cesium-131, a cancer fighting isotope that is currently used to treat a broad range of cancers. The company’s primary focus at present is Prostrate Cancer – a treatment market valued at $5.63B in 2016, but expected to reach $18.4B by 2025.
However, the company’s unique and promising “Cesium-131 brachytherapy” approach is expected to expand into the treatment of both brain and head and neck cancers before long.
This is a company has begun to show not only leading tech, but also an ability to post serious and sustained top line revenue growth. And the chart makes it awfully clear the stock is starting to spark some major interest, with a recent glaring breakout above major moving averages on some serious volume.
The early money is finding this one, but there’s still time to get on board ahead of the crowd… if you move fast!
Company: IsoRay Inc.
Latest News: http://finance.yahoo.com/q/h?s=ISR+Headlines